- Transforming inert cycloalkanes into α,ω-diamines by designed enzymic cascade catalysisBy Zhang, Zhongwei et al, Angewandte Chemie, 2023, 62(16), e202215935
Cas no 53-57-6 (NADPH)
NADPH Chemical and Physical Properties
Names and Identifiers
-
- [[(2S,3S,4S,5S)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxy-te trahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] [(2S,3R,4S,5S)-5-( 3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]m et
- Adenosine5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'®
- β-NADPH-d4
- 5'-ester with 1,4-dihydro-1-b-D-ribofuranosyl-3-pyri
- 5'-ester with 1,4-dihydro-1-b-D-ribofuranosyl-3-pyridinecarboxamide
- Di-(tert-butyl) imidodicarbonate
- Di-t-butyl iminodicarboxylate
- di-tert-butyl imidodicarbonate
- di-tert-butyl iminodicarbonate
- Di-tert-butyl Iminodicarboxylate
- Di-tert-butyl-iminodicarboxylate
- Iminodicarboxylic Acid Di-tert-butyl Ester
- N-Boc-tert-butylcarbamate
- tert-Butyl iminodicarboxylate
- β-TPNH
- β-Nicotinamide-adenine-dinucleotide-phosphoric acid
- β-NADPH
- Triphosphopyridine nucleotide, reduced
- TPNH
- Reduced triphosphopyridine nucleotide
- Reduced nicotinamide adenine dinucleotide phosphate
- Reduced 2 codehydrogenase II
- Nicotinamide-adenine dinucleotide phosphate, reduced
- NADPH
- Dihydrocodehydrogenase II
- Cozymase II, reduced
- Coenzyme II, reduced
- Codehydrogenase II, reduced
- Codehydrase II, reduced
- 51: PN: WO2004076659 FIGURE: 7 claimed sequence
- Adenosine, 2'-(dihydrogen phosphate) 5'-(trihydrogen pyrophosphate), 5'→5'-ester with 1,4-dihydro-1-β-D-ribofuranosylnicotinamide (8CI)
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'→5'-ester with 1,4-dihydro-1-β-D-ribofuranosyl-3-pyridinecarboxamide
- 53-57-6
- b-Nicotinamide-adenine-dinucleotide-phosphorate
- Dihydrocodehydrogenase II
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
- C21-H30-N7-O17-P3.4Na
- NADP REDUCED FORM [MI]
- ACFIXJIJDZMPPO-NNYOXOHSSA-N
- DTXSID001018921
- beta-Nicotinamide-adenine-dinucleotide-phosphoric acid
- C00005
- C21H30N7O17P3
- DB02338
- Nicotinamide-adenine-dinucleotide-phosphorate
- CHEBI:16474
- EINECS 200-177-6
- ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE), 2'-(DIHYDROGEN PHOSPHATE), P'->5'-ESTER WITH 1,4-DIHYDRO-1-.BETA.-D-RIBOFURANOSYL-3-PYRIDINECARBOXAMIDE
- beta-Nicotinamide-adenine-dinucleotide-phosphorate
- NADP REDUCED FOM
- C21-H30-N7-O17-P3
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
- reduced Cozymase II
- beta-NADPH Tetrasodium
- CHEMBL407009
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), 5'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
- Reduced Nicotinamide Adenine Dinucleotide Phosphate
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'?5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
- reduced nicotinamide-adenine dinucleotide phosphate
- REDUCED CODEHYDROGENASE II
- COENZYME II, REDUCED
- dihydrotriphosphopyridine nucleotide reduced
- NADPH
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogenphosphate), P'-5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
- Reduced triphosphopyridine nucleotide
- reducednicotinamide-adenine dinucleotide phosphate
- NADPH2
- reduced Coenzyme II
- .BETA.-NADPH
- 2646-71-1
- Nicotinamide-adenine-dinucleotide-phosphoric acid
- 2'-(dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) Adenosine 5'-ester with 1,4-dihydro-1-b-D-ribofuranosylnicotinamide
- dihydronicotinamide adenine dinucleotide-P
- Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) P'-5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosyl-3-pyridinecarboxamide
- TPNH
- Nicotinamide-adenine dinucleotide phosphate, reduced
- NADP-reduced
- b-NADPH
- Triphosphopyridine nucleotide reduced
- .BETA.-NICOTINAMIDE-ADENINE-DINUCLEOTIDE-PHOSPHORIC ACID
- Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) P'-5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
- [[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
- 2'-O-phosphonoadenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}
- beta-NADPH
- dihydronicotinamide adenine dinucleotide phosphate
- bmse000055
- nadph hydride
- b-Nicotinamide-adenine-dinucleotide-phosphoric acid
- 2'-(dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) Adenosine 5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosylnicotinamide
- 381Q4X082D
- Nicotinamide adenine dinucleotide phosphate - reduced
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
- reduced Codehydrase II
- UNII-381Q4X082D
- Q26841327
- [(2R,3R,4R,5R)-2-(6-Aminopurin-9-yl)-5-[[[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxymethyl]-4-hydroxy-oxolan-3-yl]oxyphosphonic acid
- SCHEMBL2041
- C21H30N7O17P3.4Na
- Dihydronicotinamide-adenine dinucleotide phosphate
- Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
- Adenosine, 2'-(dihydrogen phosphate) 5'-(trihydrogen pyrophosphate), 5'→5'-ester with 1,4-dihydro-1-β-D-ribofuranosylnicotinamide (8CI)
- 51: PN: WO2004076659 FIGURE: 7 claimed sequence
- Codehydrase II, reduced
- Codehydrogenase II, reduced
- Cozymase II, reduced
- Triphosphopyridine nucleotide, reduced
- β-NADPH
- β-Nicotinamide-adenine-dinucleotide-phosphoric acid
- β-TPNH
- NS00015230
- NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE
- NADPH tetraanion
- Dihydronicotinamide-adenine dinucleotide phosphoric acid
- (((2S,3S,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-((((((((2S,3R,4S,5S)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-4-hydroxyoxolan-3-yl)oxy)phosphonic acid
- NADPH dihydro-nicotinamide-adenine-dinucleotide phosphoric acid
- HY-113324
- [[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
- DA-55982
- NADP-red
- [(2S,3S,4S,5S)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
- Nucleotide, Triphosphopyridine
- 25 MG -NICOTINAMIDE ADENINE DINUCLEOTIDEPHOSPHATE REDUCED.NA4-SALT AN.GR.
- Reduced nicotinamide adenine dinucleotide phosphoric acid
- Adenosine 5'(trihydrogen diphosphate), 2'(dihydrogen phosphate), P'.fwdarw.5'ester with 1,4dihydro1betaDribofuranosyl3pyridinecarboxamide
- (((2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl)methoxy-hydroxyphosphoryl) ((2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl phosphate
- beta-TPNH
- Reduced nicotinamide-adenine dinucleotide phosphoric acid
- reduced NADP
- Dihydronicotinamideadenine dinucleotide phosphate
- {[(2S,3S,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-[({[({[(2S,3R,4S,5S)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-4-hydroxyoxolan-3-yl]oxy}phosphonic acid
- (((2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl)methoxy-hydroxyphosphoryl) ((2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate
- DTXCID201476935
- dihydronicotinamide adenine dinucleotide phosphate reduced
- Adenosine 5'(trihydrogen diphosphate), 2'(dihydrogen phosphate), P'>5'ester with 1,4dihydro1betaDribofuranosyl3pyridinecarboxamide
- dihydrotriphosphopyridine nucleotide
- NADP REDUCED FORM
- 2'-O-phosphonoadenosine 5'-(3-(1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl) dihydrogen diphosphate)
- Phosphate, Nicotinamide-Adenine Dinucleotide
- ((2S,3S,4S,5S)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl)methyl (((2S,3R,4S,5S)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy-hydroxyphosphoryl) hydrogen phosphate
- CS-0059609
- Dinucleotide Phosphate, Nicotinamide-Adenine
- Nadph dihydro-nicotinamide-adenine-dinucleotidephosphoric acid
- reduced dihydrotriphosphopyridine nucleotide
-
- Inchi: 1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
- InChI Key: ACFIXJIJDZMPPO-NNYOXOHSSA-N
- SMILES: P(=O)(O)(O)O[C@H]1[C@H](N2C=NC3C(N)=NC=NC2=3)O[C@H](COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@H](N3C=CCC(C(N)=O)=C3)O2)O)O)[C@H]1O
Computed Properties
- Exact Mass: 745.091102
- Monoisotopic Mass: 745.091102
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 9
- Hydrogen Bond Acceptor Count: 18
- Heavy Atom Count: 48
- Rotatable Bond Count: 13
- Complexity: 1410
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: _6.8
- Topological Polar Surface Area: 364
Experimental Properties
- Density: 2.28
- Boiling Point: 1175.1°Cat760mmHg
- Flash Point: 664.5°C
- Refractive Index: 1.849
- PSA: 394.57000
- LogP: -0.90060
NADPH Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | N201504-5 mg |
β-NADPH-d4 |
53-57-6 | 5mg |
$ 22380.00 | 2022-06-03 | ||
| AN HUI ZE SHENG Technology Co., Ltd. | N201504-5mg |
NADPH |
53-57-6 | 5mg |
¥237000.00 | 2023-09-15 | ||
| YAN FENG KE JI ( BEI JING ) Co., Ltd. | H47984-1g |
NADPH |
53-57-6 | 98% | 1g |
¥50.00 | 2022-10-26 | |
| YAN FENG KE JI ( BEI JING ) Co., Ltd. | H47984-5g |
NADPH |
53-57-6 | 98% | 5g |
¥130.00 | 2022-10-26 | |
| YAN FENG KE JI ( BEI JING ) Co., Ltd. | H47984-25g |
NADPH |
53-57-6 | 98% | 25g |
¥360.00 | 2022-10-26 | |
| YAN FENG KE JI ( BEI JING ) Co., Ltd. | H47984-100g |
NADPH |
53-57-6 | 98% | 100g |
¥1,050.00 | 2022-10-26 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD00799508-5g |
NADPH |
53-57-6 | 99% | 5g |
¥5103.0 | 2024-04-18 | |
| TRC | N201504-5mg |
β-NADPH-d4 |
53-57-6 | 5mg |
$ 23500.00 | 2023-02-02 | ||
| Aaron | AR00DISI-250mg |
NADPH |
53-57-6 | 99% | 250mg |
$78.00 | 2025-02-13 | |
| Aaron | AR00DISI-100mg |
NADPH |
53-57-6 | 99% | 100mg |
$46.00 | 2025-02-13 |
NADPH Production Method
Production Method 1
Production Method 2
1.2R:PhNCS, R:Et3N, S:MeCN, 1 h, rt
- The visible-light-driven transfer hydrogenation of nicotinamide cofactors with a robust ruthenium complex photocatalystBy Dong, Wenjin et al, Green Chemistry, 2020, 22(7), 2279-2287
Production Method 3
- A Photocatalyst/Enzyme Couple That Uses Solar Energy in the Asymmetric Reduction of AcetophenonesBy Choudhury, Sumit et al, Angewandte Chemie, 2012, 51(46), 11624-11628
Production Method 4
- Application of biocatalysis towards asymmetric reduction and hydrolytic desymmetrisation in the synthesis of a β-3 receptor agonistBy Badland, Matthew et al, Green Chemistry, 2011, 13(10), 2888-2894
Production Method 5
Production Method 6
- Phototriggered chemical reduction of NADP+ by Zn-reconstituted myoglobin and triethanolamine as a sacrifical donorBy Nishiyama, Katsuhiko et al, Chemistry Letters, 2005, 34(7), 1032-1033
Production Method 7
Production Method 8
Production Method 9
Production Method 10
- Polystyrene-based eosin-Y as a photocatalyst for solar light-mediated NADH/NADPH regeneration and organic transformationsBy Singh, Pooja et al, Reaction Chemistry & Engineering, 2023, 8(5), 1072-1082
Production Method 11
Production Method 12
Production Method 13
Production Method 14
- Co-production of hydrogen and ethanol by pfkA-deficient Escherichia coli with activated pentose-phosphate pathway: reduction of pyruvate accumulationBy Sekar, Balaji Sundara et al, Biotechnology for Biofuels, 2016, 9, 95/1-95/11
Production Method 15
Production Method 16
- Structural backgrounds for the formation of a catalytically competent complex with NADP(H) during hydride transfer in ferredoxin-NADP+ reductasesBy Sanchez-Azqueta, Ana et al, Biochimica et Biophysica Acta, 2012, 1817(7), 1063-1071
Production Method 17
- Enzymatic De Novo Pyrimidine Nucleotide SynthesisBy Schultheisz, Heather L. et al, Journal of the American Chemical Society, 2011, 133(2), 297-304
Production Method 18
Production Method 19
Production Method 20
- α-Secondary Isotope Effects as Probes of "Tunneling-Ready" Configurations in Enzymatic H-Tunneling: Insight from Environmentally Coupled Tunneling ModelsBy Pudney, Christopher R. et al, Journal of the American Chemical Society, 2006, 128(43), 14053-14058
Production Method 21
Production Method 22
Production Method 23
NADPH Raw materials
- Sodium Bicarbonate-13C
- NADP
- L-Aspartic acid-
- D(+)-Glucose
- 2-Ketoglutaric acid
- 2-Chloro-1-(6-chloropyridin-3-yl)ethanone
- D(-)-Sorbitol Standard
- Glycerol
- b-Nicotinamide Adenine Dinucleotide
- D-Glucose-13C6
NADPH Preparation Products
- D-Gluconic acid (526-95-4)
- L-Glutamic acid (56-86-0)
- Creatine (57-00-1)
- butanedioic acid (110-15-6)
- 1,8-Diaminooctane (373-44-4)
- Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-β-D-ribofuranosyl-3-pyridinecarboxamide (58-68-4)
- NADPH (53-57-6)
- Adenosine 5'-Diphosphate (58-64-0)
- (1R)-2-chloro-1-(6-chloro-3-pyridyl)ethanol (477259-60-2)
- Uridine-1',2,2',3',4',5'-13C6 5'-(tetrahydrogen triphosphate) (1310054-16-0)
NADPH Suppliers
NADPH Related Literature
-
Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
-
David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
-
Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
-
Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
Additional information on NADPH
Beta-NADPH-d4: A Comprehensive Overview
Beta-NADPH-d4, also known as β-NADPH-d4, is a deuterated derivative of β-nicotinamide adenine dinucleotide phosphate (β-NADPH). With the CAS number 53-57-6, this compound plays a crucial role in various biochemical processes, particularly in cellular metabolism and redox reactions. The deuterium labeling in β-NADPH-d4 makes it an invaluable tool in isotopic studies, enabling researchers to track metabolic pathways with unparalleled precision.
The structure of β-NADPH-d4 consists of a nicotinamide group, a ribose sugar, and an adenine nucleotide, with the addition of four deuterium atoms. This deuterium substitution enhances the compound's stability and provides a unique signature for analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. Recent advancements in isotopic labeling techniques have further expanded the applications of β-NADPH-d4 in metabolic flux analysis and enzyme kinetics studies.
In cellular biology, β-NADPH is a key cofactor in biosynthetic reactions and acts as a reducing agent in processes like fatty acid synthesis and glutathione production. The d4 variant allows researchers to distinguish between endogenous and exogenous NADPH pools, which is critical for understanding cellular homeostasis. For instance, studies using β-NADPH-d4 have shed light on the interplay between glycolysis and the pentose phosphate pathway in cancer cells, revealing novel therapeutic targets.
From a biochemical standpoint, β-NADPH-d4 is often utilized in assays to measure enzyme activity, particularly for enzymes such as glucose-6-phosphate dehydrogenase (G6PD) and malic enzyme. These assays are essential for diagnosing metabolic disorders and evaluating the efficacy of potential drug candidates. Recent research has also explored the use of β-NADPH-d4 in studying redox signaling pathways, highlighting its role in inflammation and oxidative stress responses.
In terms of applications, β-NADPH-d4 is widely used in academia and industry for metabolomics studies, drug discovery, and basic research. Its ability to serve as a tracer in complex biological systems makes it indispensable for understanding metabolic networks. Furthermore, advancements in mass spectrometry have enabled high-resolution detection of β-NADPH-d4, facilitating its use in large-scale metabolomic analyses.
Looking ahead, the demand for β-NADPH-d4 is expected to grow as researchers continue to unravel the complexities of cellular metabolism. Its role in personalized medicine and precision healthcare is particularly promising, with potential applications in disease modeling and therapeutic development. As technology evolves, so too will the capabilities of this versatile compound.
53-57-6 (NADPH) Related Products
- 100929-71-3(NADPH tetracyclohexanamine)
- 104076-88-2(Adenosine5'-(trihydrogen diphosphate), P'®5'-ester with (1,4-dihydro-1-b-D-ribofuranosyl-3-pyridinyl)phenylmethanone (9CI))
- 108321-28-4(Adenosine5'-(trihydrogen diphosphate), 3'-(dihydrogen phosphate), P'®5'-ester with 1,4-dihydro-1-a-D-ribofuranosyl-3-pyridinecarboxamide,sodium salt (9CI))
- 108321-31-9(Adenosine5'-(trihydrogen diphosphate), P'®5'-ester with 1,4-dihydro-1-a-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt (9CI))
- 134388-69-5(Adenosine5'-(trihydrogen diphosphate), 8-azido-, P'®5'-ester with 1,4-dihydro-1-b-D-ribofuranosyl-3-pyridinecarboxamide(9CI))
- 110241-41-3(Adenosine5'-(trihydrogen diphosphate), P'®5'-ester with 3-formyl-1,4-dihydro-a-oxo-1-b-D-ribofuranosyl-4-pyridinepropanoic acid (9CI))
- 606-68-8(b-NADH Disodium Salt)
- 2646-71-1(NADPH tetrasodium salt)
- 102029-93-6(3-Acetylpyridine Adenine Dinucleotide, Reduced Form, Sodium Salt)
- 104809-32-7(Adenosine5'-(trihydrogen diphosphate), P'®5'-ester with 1,4-dihydro-1-b-D-ribofuranosyl-3-pyridinecarboxamide, dipotassium salt (9CI))